

SAVELLA (milnacipran)

GPI CODING:

Savella 100 mg	62504050100350
Savella 25 mg	62504050100330
Savella 50 mg	62504050100340
Savella Tabs 12.5 mg	62504050100320
Savella Titration Pack	62504050106320

DESCRIPTION:

Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI); it inhibits norepinephrine uptake with greater potency than serotonin. Norepinephrine and serotonin are two neurotransmitters thought to play a central role in the symptoms of fibromyalgia. The exact mechanism of the central pain inhibitory action of milnacipran and its ability to improve the symptoms of fibromyalgia in humans are unknown. Milnacipran is FDA-approved for the management of fibromyalgia.

APPROVAL DURATION:

Initial approvals and renewals: 12 months

CRITERIA FOR SAVELLA

- I. Patient has a diagnosis of fibromyalgia with widespread pain (on the left and right side of the body, above and below the waist), present for at least 3 months **AND**
- II. Patient has axial skeletal pain (cervical pain or anterior chest or thoracic spine or low back), present for at least 3 months **AND**
- III. Patient has at least 11 out of 18 positive (painful) specific bilateral tender point sites (e.g. occiput, low cervical, trapezius, supraspinatus, second rib, lateral, epicondyle, gluteal, greater trochanter, or knee) after digital palpitation with an approximate force of 4 kg **AND**
- IV. Patient has tried and failed at least one of the following medications:
 - A. Cyclobenzaprine
 - B. Fluoxetine
 - C. A tricyclic antidepressant
 - D. Lyrica
 - E. Cymbalta